Rebion’s Traq.™ device leverages Neural Performance Scanning (NPS) to detect impairments related to visual tracking.

Currently in pivotal clinical trials, Rebion’s Traq.™ device looks for physical and structural disruptions within the brain-eye pathway. This previously unavailable measurement of the brain/retina/eye continuum may provide an objective assessment of the neurophysiological mechanisms tied to impairments.

Based on years of R&D into new technologies at major medical institutions, Rebion manufactures innovative devices for definitively identifying life-altering diseases that manifest from functional impairments in the brain; most notably, lazy eye and traumatic brain injury.

By rapidly assessing brain function, Rebion’s TraqTM device can provide a functional assessment at each touch point along the TBI patient journey from injury to recovery (or lack of recovery). Rebion is competing against outdated and ineffective technologies.

Nov 21, 2024 · By rapidly assessing brain function, Rebion’s TraqTM device can provide a functional assessment at each touch point along the TBI patient journey from injury to recovery (or lack of recovery). Rebion is competing against outdated and ineffective technologies.

Apr 6, 2022 · The NPS technology to be used at BU will be Rebion's Traq™ device, which provides a non-invasive scan of the retinas to measure functional impairment along the brain-eye pathway.

Sep 9, 2023 · Rebion is also completing pivotal trials for its second device, Traq., which seeks to characterize the relationship between disruptions in the brain-eye pathway and traumatic brain injury (TBI).

Apr 6, 2022 · Rebion (Rebiscan, Inc.), a medical-device company building and further developing neuro-ocular scanning devices, has been granted a two-year award to collaborate with Boston University (BU) in a pursuit to accurately monitor recovery from traumatic brain injuries (TBI).

Rebion’s devices identify a host of brain function impairments including lazy eye, traumatic brain injury, chemical impairment, and neurodegenerative disorders. Rebion point-of-care devices are designed to lower the cost of care and increase the quality of outcomes.

Mark For: TRAQ™ trademark registration is intended to cover the category of medical device that scans the eyes for assessment of traumatic brain injury.